Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients

Journal of Translational Medicine

Valerio Pazienza⁵  Angelo Andriulli⁵  Pierluigi di Sebastiano⁷  Fabio Francesco di Mola⁷  Manlio Vinciguerra¹  Paolo Graziano⁴  Lucia Lombardi²  Evaristo Maiello²  Massimiliano Copetti⁸  Francesco Cappello³  Francesca Rappa³  Francesca Paola Burbaci⁵  Fabio Pellegrini⁶  Andrea Fontana⁸  Francesca Tavano⁵ 

[1] University College London, Institute for Liver and Digestive Health, Division of Medicine, Royal Free Campus, London, UK;Oncology Unit I.R.C.C.S. ¿Casa Sollievo della Sofferenza¿ Hospital San Giovanni Rotondo (FG) Italy, viale dei Cappuccini n.1, San Giovanni Rotondo 71013, FG, Italy;Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Palermo, Italy;Pathology Unit I.R.C.C.S. ¿Casa Sollievo della Sofferenza¿ Hospital San Giovanni Rotondo (FG) Italy, viale dei Cappuccini n.1, San Giovanni Rotondo 71013, FG, Italy;Gastroenterology Unit, I.R.C.C.S. ¿Casa Sollievo della Sofferenza¿ Hospital San Giovanni Rotondo (FG) Italy, viale dei Cappuccini n.1, San Giovanni Rotondo 71013, FG, Italy;Unit of Biostatistics, DCPE, Consorzio Mario Negri Sud, Santa Maria Imbaro, CH, Italy;Division of Surgical Oncology ¿SS Annunziata¿ Hospital, Chieti, Italy;Unit of Biostatistics I.R.C.C.S. ¿Casa Sollievo della Sofferenza¿ Hospital San Giovanni Rotondo (FG) Italy, viale dei Cappuccini n.1, San Giovanni Rotondo 71013, FG, Italy

关键词: RECPAM;    DCK;    MRP1;    CHOP;    hENT1;    Pancreatic ductal adenocarcinoma;   

Others  :  1148091
DOI  :  10.1186/s12967-014-0248-4

 received in 2014-05-06, accepted in 2014-08-29,  发布年份 2014

【 摘 要 】

Background

Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive malignancy, characterized by largely unsatisfactory responses to the currently available therapeutic strategies. In this study we evaluated the expression of genes involved in gemcitabine uptake in a selected cohort of patients with PDAC, with well-defined clinical-pathological features.

Methods

mRNA levels of hENT1, CHOP, MRP1 and DCK were evaluated by means of qRT-PCR in matched pairs of tumor and adjacent normal tissue samples collected from PDAC patients treated with gemcitabine after surgical tumor resection. To detect possible interaction between gene expression levels and to identify subgroups of patients at different mortality/progression risk, the RECursive Partitioning and Amalgamation (RECPAM) method was used.

Results

RECPAM analysis showed that DCK and CHOP were most relevant variables for the identification of patients with different mortality risk, while hENT1 and CHOP were able to identify subgroups of patients with different disease progression risk. Conclusion: hENT1, CHOP, MRP1 and DCK appear correlated to PDAC, and this interaction might influence disease behavior.

【 授权许可】

   
2014 Tavano et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
• [2]Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 1999, 49(1):8-31.
• [3]Warshaw AL, Fernández-del Castillo C: Pancreatic carcinoma. N Engl J Med 1992, 13;326(7):455-465.
• [4]Hariharan D, Saied A, Kocher HM: Analysis of mortality rates for pancreatic cancer across the world. HPB (Oxford) 2008, 10(1):58-62.
• [5]Abbruzzese JL: New applications of gemcitabine and future directions in the management of pancreatic cancer. Cancer 2002, 95(4 Suppl):941-945.
• [6]Rathos MJ, Joshi K, Khanwalkar H, Manohar SM, Joshi KS: Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers. J Transl Med 2012, 10:161. BioMed Central Full Text
• [7]Ballehaninna UK, Chamberlain RS: Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19¿9. Tumour Biol 2013, 34(6):3279-3292.
• [8]Di Gangi I, Vrovsek U, Pazienza V, Mattivi F: Analytical metabolomics-based approaches to pancreatic cancer. Trends Anal Chem 2014, 55:94-116.
• [9]Zhang J, Visser F, King KM, Baldwin SA, Young JD, Cass CE: The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev 2007, 26(1):85-110.
• [10]Pérez-Torras S, García-Manteiga J, Mercadé E, Casado FJ, Carbó N, Pastor-Anglada M, Mazo A: Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer. Biochem Pharmacol 2008, 76(3):322-329.
• [11]Wang H, Word BR, Lyn-Cook BD: Enhanced efficacy of gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrative nucleoside transporter 1. Anticancer Res 2011, 31(10):3171-3180.
• [12]Eto K, Kawakami H, Kuwatani M, Kudo T, Abe Y, Kawahata S, Takasawa A, Fukuoka M, Matsuno Y, Asaka M, Sakamoto N: Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer. Br J Cancer 2013, 108(7):1488-1494.
• [13]Santini D, Vincenzi B, Fratto ME, Perrone G, Lai R, Catalano V, Cass C, Ruffini PA, Spoto C, Muretto P, Rizzo S, Muda AO, Mackey JR, Russo A, Tonini G, Graziano F: Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer. J Cell Physiol 2010, 223(2):384-388.
• [14]Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR: Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009, 136(1):187-195.
• [15]Ohhashi S, Ohuchida K, Mizumoto K, Fujita H, Egami T, Yu J, Toma H, Sadatomi S, Nagai E, Tanaka M: Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer. Anticancer Res 2008, 28(4B):2205-2212.
• [16]Noma B, Sasaki T, Fujimoto Y, Serikawa M, Kobayashi K, Inoue M, Itsuki H, Kamigaki M, Minami T, Chayama K: Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer. Int J Oncol 2008, 33(6):1187-1194.
• [17]Miller DW, Fontain M, Kolar C, Lawson T: The expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines. Cancer Lett 1996, 107(2):301-306.
• [18]Su N, Kilberg MS: C/EBP homology protein (CHOP) interacts with activating transcription factor 4 (ATF4) and negatively regulates the stress-dependent induction of the asparagine synthetase gene. J Biol Chem 2008, 283(50):35106-35117.
• [19]Pandolfi A, Di Pietro N: High glucose, nitric oxide, and adenosine: a vicious circle in chronic hyperglycaemia? Cardiovasc Res 2010, 86(1):9-11.
• [20]Pazienza V, Tavano F, Benegiamo G, Vinciguerra M, Burbaci FP, Copetti M, di Mola FF, Andriulli A, di Sebastiano P: Correlations among PPAR?, DNMT1, and DNMT3B Expression Levels and Pancreatic Cancer. PPAR Res 2012, 2012:461784.
• [21]Rappa F, Greco A, Podrini C, Cappello F, Foti M, Bourgoin L, Peyrou M, Marino A, Scibetta N, Williams R, Mazzoccoli G, Federici M, Pazienza V, Vinciguerra M: Immunopositivity for histone macroH2A1 isoforms marks steatosis-associated hepatocellular carcinoma. PLoS One 2013, 8(1):e54458.
• [22]Ciampi A: Generalized Regression Tree. Comput Stat Data Anal 1991, 12(1):57-78.
• [23]Barbano R, Muscarella LA, Pasculli B, Valori VM, Fontana A, Coco M, la Torre A, Balsamo T, Poeta ML, Marangi GF, Maiello E, Castelvetere M, Pellegrini F, Murgo R, Fazio VM, Parrella P: Aberrant Keap1 methylation in breast cancer and association with clinicopathological features. Epigenetics 2013, 8(1):105-112.
• [24]Hagmann W, Jesnowski R, Löhr JM: Interdependence of Gemcitabine Treatment, Transporter Expression, and Resistance in Human Pancreatic Carcinoma Cells. Neoplasia 2010, 12:740-747.
• [25]Nishio R, Tsuchiya H, Yasui T, Matsuura S, Kanki K, Kurimasa A, Hisatome I, Shiota G: Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd). Cancer Sci 2011, 102:622-629.
• [26]Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R, Mackey JR: The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma. Clin Cancer Res 2004, 10(20):6956-6961.
• [27]Nakagawa N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Sueda T: Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection. Surgery 2013, 153(4):565-575.
• [28]Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D, Del Chiaro M, Iannopollo M, Bevilacqua G, Mosca F, Danesi R: Transcription Analysis of Human Equilibrative Nucleoside Transporter-1 Predicts Survival in Pancreas Cancer Patients Treated with Gemcitabine. Cancer Res 2006, 66(7):3928-3935.
• [29]Benassai G1, Mastrorilli M, Quarto G, Cappiello A, Giani U, Forestieri P, Mazzeo F: Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol 2000, 73(4):212-218.
• [30]Sohn TA1, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD: Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000, 4(6):567-579.
• [31]Strasberg SM, Gao F, Sanford D, Linehan DC, Hawkins WG, Fields R, Carpenter DH, Brunt EM, Phillips C: Jaundice: an important, poorly recognized risk factor for diminished survival in patients with adenocarcinoma of the head of the pancreas. HPB (Oxford) 2014, 16(2):150-156.
• [32]Changchien CS, Yung CY, Tzen KY: Serum CEA and CA 19¿9 value in patients with pancreatic cancer or pancreatitis. Changgeng Yi Xue Za Zhi 1991, 14(1):32-38.
• [33]Lundin J1, Roberts PJ, Kuusela P, Haglund C, Haglund : The prognostic value of preoperative serum levels of CA 19¿9 and CEA in patients with pancreatic cancer. Br J Cancer 1994, 69(3):515-519.
• [34]Fukushima N, Hruban RH, Kato Y, Klimstra DS, Kloppel G, Shimizu N, Terris B: Ductal adenocarcinoma variants and mixed neoplasms of the pancreas. In WHO classification of tumors of the digestive system. Edited by Bosman FT, Carneiro F, Hruban RH, Theise ND. IARC, Lyon; 2008:292-299.
• [35]Greenhalf W, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Lamb RF, Garner E, Campbell F, Mackey JR, Costello E, Moore MJ, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Halloran CM, Mayerle J, Oláh A, Jackson R, Rawcliffe CL, Scarpa A, Bassi C, Büchler MW: Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst 2014, 106(1):djt347. doi:10.1093/jnci/djt347